AR060401A1 - Derivados de cromen-2-ona - Google Patents

Derivados de cromen-2-ona

Info

Publication number
AR060401A1
AR060401A1 ARP070101499A ARP070101499A AR060401A1 AR 060401 A1 AR060401 A1 AR 060401A1 AR P070101499 A ARP070101499 A AR P070101499A AR P070101499 A ARP070101499 A AR P070101499A AR 060401 A1 AR060401 A1 AR 060401A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
alkoxy
halo
hydrogen
Prior art date
Application number
ARP070101499A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR060401A1 publication Critical patent/AR060401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Procesos para su produccion, sus usos, en particular en trasplante, y composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de la formula 1, en donde cada uno de R1 y R2 se selecciona independientemente a partir del grupo que consiste en hidrogeno; halogeno; nitro; alquilo C1-8 opcionalmente sustituido; halo-alquilo C1-8 opcionalmente sustituido; alquilo C1-8-carbonilo opcionalmente sustituido; alquinilo C1-8 opcionalmente sustituido; alcoxilo C1-8 opcionalmente sustituido; halo-alcoxilo C1-8 opcionalmente sustituido; alquinilo C1-8; cicloalquilo C3-6 opcionalmente sustituido; cicloalquiloxilo C3-8 opcionalmente sustituido; residuo heterocíclico; arilo opcionalmente sustituido; o R1 y R2 forman juntos un cicloalquilo C3-8 opcionalmente sustituido, o un residuo heterocíclico; R3 es hidrogeno; halogeno; alquilo C1-8 opcionalmente sustituido; alcoxilo C1-8 opcionalmente sustituido; halo-alcoxilo C1-8 opcionalmente sustituido; alquenilo C1-8; R4 es de la formula: alquilo C1-2-NRcRd, en donde: el alquilo C1-2 está opcionalmente sustituido, o está sustituido por dos residuos de alquilo sobre el mismo átomo de carbono, en donde los dos residuos de alquilo forman opcionalmente, junto con el átomo de carbono con el que están enlazados, un cicloalquilo C3-8; cada uno de Rc y Rd se selecciona independientemente a partir del grupo que consiste en hidrogeno; alquilo C1-8 opcionalmente sustituido; halo-alquilo C1-8; cicloalquilo C3-6; alquilo C1-8- carbonilo; alcoxilo C1-6-carbonilo; y alquino C1-6; o Rc y Rd forman, junto con el átomo de nitrogeno con el que están enlazados, un residuo heterocíclico opcionalmente sustituido; y R4 está en la posicion 3 o 4; R5 es hidrogeno; hidroxilo; halogeno; halo-alquilo C1-8; alquilo C1-8 opcionalmente sustituido; alcoxilo C1-8 o halo-alcoxilo C1-8; y R5 está en la posicion 2 o 3; o R4 y R5 están en la posicion 4 y 3, respectivamente, y forman juntos un residuo heterocíclico; el anillo A no comprende heteroátomo alguno, o comprende 1 o 2 heteroátomos del anillo; con la condicion de que R1 y R2 no son ambos hidrogeno; o un derivado fisiologicamente hidrolizable del mismo, una sal, hidrato, y/o solvato del mismo.
ARP070101499A 2006-04-12 2007-04-10 Derivados de cromen-2-ona AR060401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0607389.4A GB0607389D0 (en) 2006-04-12 2006-04-12 Organic compounds

Publications (1)

Publication Number Publication Date
AR060401A1 true AR060401A1 (es) 2008-06-11

Family

ID=36571719

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101499A AR060401A1 (es) 2006-04-12 2007-04-10 Derivados de cromen-2-ona

Country Status (16)

Country Link
US (1) US20090318546A1 (es)
EP (1) EP2010511A1 (es)
JP (1) JP2009534315A (es)
KR (1) KR20090004945A (es)
CN (1) CN101421260A (es)
AR (1) AR060401A1 (es)
AU (1) AU2007236114B2 (es)
BR (1) BRPI0710130A2 (es)
CA (1) CA2644951A1 (es)
CL (1) CL2007001023A1 (es)
GB (1) GB0607389D0 (es)
MX (1) MX2008013123A (es)
PE (1) PE20080056A1 (es)
RU (1) RU2008144487A (es)
TW (1) TW200815387A (es)
WO (1) WO2007115820A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092930A1 (en) * 2007-02-02 2008-08-07 Novartis Ag Chromene s1p1 receptor antagonist
KR20180023049A (ko) 2008-07-23 2018-03-06 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
CN105816453B (zh) 2008-08-27 2021-03-05 艾尼纳制药公司 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
KR101102952B1 (ko) * 2009-03-05 2012-01-10 주식회사 문인 크린룸용 창문 프레임
WO2011050054A2 (en) 2009-10-23 2011-04-28 Allergan, Inc. Coumarin compounds as receptor modulators with therapeutic utility
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
SG10201501575VA (en) 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
US20140235592A1 (en) * 2013-02-21 2014-08-21 Allergan, Inc. Substituted 6-methoxy-4-amino-n-phenyl-2-naphtamides as sphingosine receptor modulators
CN103265517B (zh) * 2013-05-11 2016-01-13 浙江大学 3-取代香豆素类衍生物及其用途
ES2534336B1 (es) 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno como inhibidores de la interacción TCR-Nck
ES2534318B1 (es) 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck
KR20230151072A (ko) 2015-01-06 2023-10-31 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
CA3002551A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
MX2020008814A (es) 2018-02-27 2020-12-11 Artax Biopharma Inc Derivados de cromeno como inhibidores de la interaccion receptor de antigeno de celula t (tcr) - region no catalitica de la proteina citosolica de la proteina tirosina cinasa (nck).
CN108715589B (zh) * 2018-06-19 2021-04-20 华侨大学 一种用作caspase-3激活剂的香豆素类衍生物及其应用
KR20210074291A (ko) 2018-09-06 2021-06-21 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한 화합물
CN111747917B (zh) * 2020-07-28 2022-09-13 遵义医科大学 一种蛇床子素酰胺类化合物及其应用
CN113402491A (zh) * 2021-06-15 2021-09-17 山东大学苏州研究院 一种香豆素酰胺类化合物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763944B1 (fr) * 1997-06-03 2000-12-15 Centre Nat Rech Scient Nouveaux derives de coumarines, leurs procedes de preparation et leur application comme medicaments en tant qu'inhibiteurs de proteases
NZ536291A (en) * 2002-04-19 2006-09-29 Signal Pharm Inc Benzopyranone compounds, compositions thereof, and methods of treatment therewith
CN1506359A (zh) * 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
MXPA06002876A (es) * 2003-09-15 2006-06-05 Signal Pharm Llc Compuestos de benzopiranona, composiciones de los mismos y metodos de tratamiento que los utilizan.
EP1828144A2 (en) * 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents

Also Published As

Publication number Publication date
CA2644951A1 (en) 2007-10-18
BRPI0710130A2 (pt) 2011-08-02
EP2010511A1 (en) 2009-01-07
TW200815387A (en) 2008-04-01
GB0607389D0 (en) 2006-05-24
MX2008013123A (es) 2008-10-21
JP2009534315A (ja) 2009-09-24
PE20080056A1 (es) 2008-03-26
KR20090004945A (ko) 2009-01-12
CN101421260A (zh) 2009-04-29
WO2007115820A1 (en) 2007-10-18
CL2007001023A1 (es) 2008-03-14
AU2007236114B2 (en) 2010-12-02
US20090318546A1 (en) 2009-12-24
RU2008144487A (ru) 2010-05-20
AU2007236114A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
AR060401A1 (es) Derivados de cromen-2-ona
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
PE20190709A1 (es) Derivado de pirazolopiridinaque tiene el efecto agonista del receptor de glp-1
PE20121159A1 (es) DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR082562A1 (es) Derivados de isoxazolina como agentes antiparasitarios
CO6251251A2 (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
AR079224A1 (es) Compuestos insecticidas basados en derivados de isoxazolina
AR083081A1 (es) Isoxazolin oximas como agentes antiparasitarios
AR056964A1 (es) Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR075635A1 (es) N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR080841A1 (es) Derivados de isoxazolina sustituida; composiciones veterinarias que los comprenden y su uso en el tratamiento de parasitos en animales
CO6251271A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
AR063723A1 (es) 5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatorios
PE20150399A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6170061A1 (es) Compuestos de pirandiona, tiopirandiona y ciclohexantriona utiles como herbicidas, procesos para su preparacion, intermediarios utiles en su preparacion, metodos para controlar hierbas y malezas en cultivos de plantas utiles utilizando dichos herbici
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
AR064066A1 (es) Un agente para tratamiento del suelo o agente para el tratamiento de la semilla que comprende compuestos de quinolina o sus sales como un componente activo, o un metodo para prevenir las enfermedades de plantas por el uso de este.
AR066605A1 (es) Derivados de heteroarilamida pirimidona
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
PE20160240A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR100530A1 (es) Compuestos antihelmínticos
AR070263A1 (es) Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios.

Legal Events

Date Code Title Description
FB Suspension of granting procedure